Business Insider

Pivotal study reports InSure® FIT™ offers superior sensitivity for colorectal cancer screeningInSure FIT more sensitive than OC FIT-CHEK and Hemoccult II SENSA for detecting ...

BRIDGEWATER, N.J., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Clinical Genomics, manufacturer of fecal immunochemical tests for colorectal cancer screening programs, announces that in a study of more than 1000 ...
Becker's Hospital Review

Clinical Genomics and Quest Diagnostics extend collaboration to provide InSure® ONE™, a fecal immunochemical test for colorectal cancer screening programs

Clinical Genomics, a leading innovator of tests for colorectal cancer, and Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced a 5-year ...
Becker's ASC

Clinical Genomics’ fecal occult blood test ‘significantly more’ sensitive than competitors

Clinical Genomics’ fecal occult blood test InSure FIT was more effective than two other leading tests in a study of 1,000-plus people, according to a study published in The American Journal of ...
Becker's Hospital Review

Clinical Genomics and Quest Diagnostics announce FDA 510(K) clearance of InSure® ONE™

At-home collection, one-day fecal immunochemical test that meets American Cancer Society guidelines and HEDIS quality measures for lower gastrointestinal bleeding screening programs A number of ...
Monthly Prescribing Reference

FDA Approves InSure One to Aid in Detecting Lower GI Bleeding

The InSure ONE requires a sample of water from the toilet bowl, after the stool surface has been brushed to release any blood. The Food and Drug Administration (FDA) has cleared ‘InSure ONE’, an ...